SomnoMed Limited

ASX:SOM Stock Report

Market Cap: AU$91.8m

SomnoMed Future Growth

Future criteria checks 1/6

SomnoMed is forecast to grow revenue at 10.2% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth16.0%
Revenue growth rate10.2%
Future return on equity3.2%
Analyst coverage

Low

Last updated03 Dec 2024

Recent future growth updates

Recent updates

SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 02
SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

Oct 16
Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

Jul 15
SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

May 31
SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 15
SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Mar 04
SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

Dec 21
Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Sep 02
SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Jun 19
Is SomnoMed (ASX:SOM) Using Too Much Debt?

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

Nov 18
It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Sep 27
SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

May 10
Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Oct 26
Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

May 12
Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Mar 02
Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Feb 01
Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Dec 28
Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Dec 01
Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

Jul 28
Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Jul 14
SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Earnings and Revenue Growth Forecasts

ASX:SOM - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2027126N/AN/AN/A1
6/30/2026115N/AN/AN/A1
6/30/2025105N/AN/AN/A1
6/30/202492-12-12-6N/A
3/31/202490-11-11-6N/A
12/31/202389-11-10-5N/A
9/30/202386-9-10-4N/A
6/30/202384-8-10-4N/A
3/31/202381-7-11-3N/A
12/31/202279-5-11-2N/A
9/30/202276-5-90N/A
6/30/202273-4-72N/A
3/31/202269-5-61N/A
12/31/202166-5-6-1N/A
9/30/202164-3-41N/A
6/30/202163-1-13N/A
3/31/202159-125N/A
12/31/202055-157N/A
9/30/202056-146N/A
6/30/202057035N/A
3/31/202060002N/A
12/31/2019631-4-1N/A
9/30/2019610-6-4N/A
6/30/2019590-8-7N/A
3/31/2019582N/AN/AN/A
12/31/2018563-9-7N/A
9/30/2018543-10-8N/A
6/30/2018522-12-9N/A
3/31/201851-1N/AN/AN/A
12/31/201750-4N/A-8N/A
9/30/201750-4N/A-5N/A
6/30/201749-3N/A-3N/A
3/31/201748-2N/A-1N/A
12/31/201647-1N/A0N/A
9/30/2016450N/A1N/A
6/30/2016440N/A2N/A
3/31/2016420N/A2N/A
12/31/2015391N/A1N/A
9/30/2015371N/A0N/A
6/30/2015341N/A0N/A
3/31/2015341N/A0N/A
12/31/2014351N/A-1N/A
9/30/2014321N/A-1N/A
6/30/2014300N/A-1N/A
3/31/2014260N/A0N/A
12/31/2013220N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SOM's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if SOM's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if SOM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SOM's revenue (10.2% per year) is forecast to grow faster than the Australian market (5.8% per year).

High Growth Revenue: SOM's revenue (10.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SOM's Return on Equity is forecast to be low in 3 years time (3.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:29
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SomnoMed Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightAPP Securities Pty Ltd.
Peter MeichelboeckSelect Equities Pty Ltd
Dr StoreyWilsons Advisory and Stockbroking Ltd.